Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma

Next Previous
Trial Profile

A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemcentinib (Primary) ; Dabrafenib; Pembrolizumab; Trametinib
  • Indications Malignant melanoma; Skin cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 24 Oct 2023 Interim Results ( database lock on August 21 2023) assessing safety and efficacy of bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma presented at the 48th European Society for Medical Oncology Congress
    • 23 Oct 2023 According to a BerGenBio media release, results from this study were presented during the European Society of Clinical Oncologists (ESMO) Annual Meeting 2023.
    • 16 Oct 2023 According to a BerGenBio media release, an oral presentation summarizing the results from this study will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top